pathway, proinflammatory cytokines have been implicated as mediators of beta-cell failure and 48 destruction causing type 1 diabetes (T1D) and type 2 diabetes (T2D) (1). Antagonism of the action of 49 the prototypic proinflammatory cytokine interleukin-1 (IL-1) improves beta-cell function in T2D 50 patients (2), an effect sustained 39 weeks beyond cessation of the antagonism in responders (3).
51
Despite a strong preclinical rationale (4) anti-IL-1 monotherapy was ineffective overall in recent-onset 52 T1D. However, IL-1 antagonism did moderate inflammation and caused a 2,5-fold higher secretory 53 function in T1D patients with intermediary beta-cell function at baseline (5, 6). Since IL-1 induced 54 beta-cell apoptosis is potentiated by other proinflammatory cytokines such as TNF, IFNg and IL-6, and 55 since anti-TNF therapy improved beta-cell function in a small placebo controlled trial (7), it is likely 56 that a combination of treatments targeting various aspects of signaling caused by the cytokine network 57 is needed to improve efficacy of anti-cytokine strategies in T1D, as has indeed been demonstrated in 58 animal models (8). Thus, there is need for novel safe therapeutic approaches for such combination 59 therapies.
60
Appropriate pulsatile insulin secretion depends on islet intercellular communication and 61 synchronization (9). Accordingly, cytokine-mediated de-synchronization of intercellular oscillating 62 calcium fluxes alters the beta cell transcriptome and sensitizes it to stress-induced impaired secretory 4 63 function and apoptosis (10). Gap junctions are intercellular channels composed of two connexin (Cx) 64 hemi-channels, each comprised of six Cx subunits (11). Cx36 is a predominant Cx in beta cells and 65 regulates insulin secretion by calcium flux synchronization (12, 13) . Other Cxs are also expressed in 66 islets (Cx43 and Cx45 in mice; Cx30.3, Cx31, Cx31.1, Cx31.9, Cx43, and Cx45 in humans), although 67 the function of these Cxs is less characterized (11, 14, 15 
Human islet culture and exposures

104
Islets from five human heart-beating organ-donors (> 80 purity, donor characteristics listed in table 1)
105
were isolated by the European Consortium for Islet Transplantation (ECIT) in Milan, Italy under local 106 approval and received in fully anonymous form, were cultured in 10% Fetal Bovine Serum (FBS), 1% penicillin/streptomycin (P/S) and 5.6mM glucose at 5% CO 2 and 37°C as described previously (27) .
108
There were no apparent differences in results obtained with islets from male or female donors, and 109 data were therefore combined.
110
Fifty human islets were pre-cultured in RPMI supplemented with 2% human serum (Life
111
Technologies, Naerum, Denmark), 1% penicillin/streptomycin (P/S) and 5.6mM glucose for 24 hours, 112 treated with or without 500nM Rotigaptide or control peptide for one hour and then exposed to 113 cytokine mixture (300pg/ml rrIL-1b+10ng/ml rhIFNg+10ng/ml rhTNFa) or control medium for 4 114 days.
115
Apoptosis and cell viability assays
116
For apoptosis assay carried out in duplicate independent cultures, DNA/histone complexes released 117 from the nucleus to the cytosol were measured using Roche cell death assay kit (Roche, Mannheim, 118 Germany) according to the manufacturer's protocol. As a surrogate of cell viability, mitochondrial formazan salt with an optical density (OD) read at 570nm.
122
Nitric oxide (NO) assay
123
As a surrogate of nitric oxide production, accumulated nitrite was measured in duplicate samples from 124 two independent parallel cultures. Supernatants (100ul) from the wells used for INS-1 cell apoptosis 125 assay were mixed with an equal volume of the Griess reagent (one part 0.1% naphtylethylene diamine 126 dihydrochloride and one part 1% sulfanilamide in 5% H3PO4 (Merck, Darmstadt, Germany), and read 127 at 550nm in a plate reader (Thermo Scientific, Naerum, Denmark). The nitrite concentration was 128 calculated using a standard curve of 0.5-40uM concentrations of NaNO 2 (Merck) as described (28). for measurement of accumulated insulin using insulin competitive ELISA assay in duplicate samples 154 from two independent parallel cultures as described (31), except that the enzyme substrate 1-step 155 Ultra TMB (3,3', 5,5;-tetramethylbenzidine) (Life Technologies) was used here.
Reactive Oxygen Species (ROS) Assay
156
Statistical analysis:
157 Data are presented as means ± SEM, and comparisons between different groups were carried 158 out by ANOVA analysis, followed by Student's paired t test using the GraphPad Prism version 6 (La 159 Jolla, USA). Bonferroni-corrected P-values ≤ 0.05 were considered as significant and ≤ 0.10 as a 160 trend.
161
Results:
162 Rotigaptide reduces cytokine-induced apoptosis in Cx43 expressing human islets.
163
Since human islets are known to express Cx43 ( fig.1a) , we examined whether the Cx43 activator RG 164 protects human islets from inflammatory-induced cell death. As expected, the cytokine combination In contrast to intact rat islets, the rat insulin-producing INS-1 cells did not express Cx43, and Cx43 To explore if RG restores cytokine-mediated inhibition of insulin biosynthesis and secretion, we 
240
The lack of protection of RG on high glucose-high lipid toxicity in INS-1 cells may be explained by 241 absence of Cx43, and these experiments should therefore be repeated in human islets, in which RG 242 would be expected to counteract glucose-mediated reduction in Cx43 expression.
243
Strengths of this study were the use of human islets to demonstrate the protective effect of RG against 244 cytokine-induced apoptosis, and the inclusion of a scrambled peptide as a control for RG. We also took 245 advantage of INS-1 cells known to lack Cx43 expression as a 'natural' Cx43 knock-out model ( fig.1a) 
246
(16, 17), thereby avoiding the risk for transfection artifacts related to shRNA knock-down or CRISPR 247 knock-out.
248
A limitation was the restricted amounts of human islets available to us for these studies, precluding 249 more mechanistic investigations such as Cx43 activity, Ca 2+ flux synchronization and studies of 250 glucose-stimulated insulin secretion. Electromobility shift assay, iNOS promotor chromatin 251 immunoprecipitation, or luciferase-based NF-kB reporter assay would help define if NF-kB promoter 252 binding or NF-KB transcriptional activity is reduced in Rotigaptide-treated islets exposed to cytokines.
253
Rotigaptide is also known to increase Cx43 half-life in cardiomyocytes by slowing its trafficking and 254 proteasomal degradation (23, 35, 36) . However, proof of Cx43 dependence of such effects of RG in 255 human islets would require knock-down or knock-out of Cx43, which is not effective in intact islets 256 but requires islet dispersion into monolayers, thereby disrupting the normal cell-to-cell contact and communication. Further research is needed to clarify if these effects contribute to the protective action 258 of Rotigaptide in human islets.
259
When added to the fact that beta-cell specific overexpression of Cx43, but not of Cx36, increases 260 pancreatic insulin content and islet size 19, our observations highlight the translational potential RG as 261 a novel approach to prevent inflammatory beta-cell failure and apoptosis in diabetes and warrant 262 further preclinical studies. The notion that RG may have a dual protective action related to its known 263 activity as a Cx43 activator and to a novel Cx43 independent inhibiting action on NF-kB activation 264 makes RG an attractive candidate for mono-or combination therapy in diabetes.
265
In conclusion, RG reduces cytokine-induced cell death in human islets, likely by preventing Cx43 
